WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
出版年份 2021 全文链接
标题
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 7, Pages e002624
出版商
BMJ
发表日期
2021-07-30
DOI
10.1136/jitc-2021-002624
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Asah2 Represses the p53–Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis
- (2021) Huabin Zhu et al. JOURNAL OF IMMUNOLOGY
- Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression
- (2021) John D. Klement et al. Cancers
- Trials and tribulations of pancreatic cancer immunotherapy
- (2021) Daniel R. Principe et al. CANCER LETTERS
- The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
- (2020) Won Jin Ho et al. Nature Reviews Clinical Oncology
- A decade of immune-checkpoint inhibitors in cancer therapy
- (2020) Caroline Robert Nature Communications
- A DNA hypomethylating drug alters the tumor microenvironment and improves the effectiveness of immune checkpoint inhibitors in a mouse model of pancreatic cancer
- (2020) Tamas A. Gonda et al. CANCER RESEARCH
- EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells
- (2020) Xingyue Zong et al. CANCER RESEARCH
- Heat shock protein-90 inhibition alters activation of pancreatic stellate cells and enhances the efficacy of PD-1 blockade in pancreatic cancer.
- (2020) Yuchen Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
- (2020) Michael Brandon Ware et al. Journal for ImmunoTherapy of Cancer
- CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
- (2020) Mark H O'Hara et al. LANCET ONCOLOGY
- CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma
- (2020) Stephen T. Muth et al. CANCER LETTERS
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
- (2019) Victoria M. Kim et al. Journal for ImmunoTherapy of Cancer
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
- (2019) Gwen Lomberk et al. Nature Communications
- Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells
- (2018) Chunwan Lu et al. BMC CANCER
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
- (2018) Zishuo I. Hu et al. CLINICAL CANCER RESEARCH
- The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis
- (2018) He-Li Gao et al. Hepatobiliary & Pancreatic Diseases International
- An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
- (2018) John D. Klement et al. JOURNAL OF CLINICAL INVESTIGATION
- Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target
- (2018) Jun Wei et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 Expression in Pancreatic Cancer
- (2017) Lei Zheng JNCI-Journal of the National Cancer Institute
- The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
- (2017) Chunwan Lu et al. JNCI-Journal of the National Cancer Institute
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- PD-L1 Expression in Pancreatic Cancer
- (2017) Lei Zheng JNCI-Journal of the National Cancer Institute
- The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
- (2017) Chunwan Lu et al. JNCI-Journal of the National Cancer Institute
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5
- (2016) Dong-Dong Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity
- (2016) Dong-Dong Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer
- (2016) Nicolas Reynoird et al. GENES & DEVELOPMENT
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- Distinct features of H3K4me3 and H3K27me3 chromatin domains in pre-implantation embryos
- (2016) Xiaoyu Liu et al. NATURE
- Structural basis for activity regulation of MLL family methyltransferases
- (2016) Yanjing Li et al. NATURE
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- The ins and outs of osteopontin
- (2015) Claudia Chiodoni et al. OncoImmunology
- Osteopontin Shapes Immunosuppression in the Metastatic Niche
- (2014) Sabina Sangaletti et al. CANCER RESEARCH
- Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes
- (2014) Florian Kahles et al. Molecular Metabolism
- Genome engineering using the CRISPR-Cas9 system
- (2013) F Ann Ran et al. Nature Protocols
- Novel Pancreatic Cancer Cell Lines Derived from Genetically Engineered Mouse Models of Spontaneous Pancreatic Adenocarcinoma: Applications in Diagnosis and Therapy
- (2013) María P. Torres et al. PLoS One
- Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction
- (2013) Yuri Bolshan et al. ACS Medicinal Chemistry Letters
- Reciprocal Interactions between Tumor-Associated Macrophages and CD44-Positive Cancer Cells via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer
- (2012) G. Rao et al. CLINICAL CANCER RESEARCH
- Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
- (2012) Y. Wang et al. CURRENT MOLECULAR MEDICINE
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
- (2008) S. Zhang et al. CANCER RESEARCH
- Osteopontin Promotes Vascular Endothelial Growth Factor Dependent Breast Tumor Growth and Angiogenesis via Autocrine and Paracrine Mechanisms
- (2008) G. Chakraborty et al. CANCER RESEARCH
- Osteopontin-c is a selective marker of breast cancer
- (2007) Mana Mirza et al. INTERNATIONAL JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search